# Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

> **NCT06008405** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** TQB2928 Injection + Azacitidine for injection

## Key facts

- **NCT ID:** NCT06008405
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008405, "Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06008405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*